Risk factors for ocular surface squamous neoplasia in Kenya: a case-control study. by Gichuhi, Stephen et al.
Gichuhi, S; Macharia, E; Kabiru, J; Zindamoyen, AM; Rono, H; Ol-
lando, E; Wachira, J; Munene, R; Onyuma, T; Jaoko, WG; Sagoo,
MS; Weiss, HA; Burton, MJ (2016) Risk factors for Ocular Sur-
face Squamous Neoplasia in Kenya; a case-control study. Tropical
medicine & international health . ISSN 1360-2276 DOI: 10.1111/tmi.12792
Downloaded from: http://researchonline.lshtm.ac.uk/2965106/
DOI: 10.1111/tmi.12792
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Risk factors for ocular surface squamous neoplasia in Kenya: a
case–control study
Stephen Gichuhi1,2, Ephantus Macharia3, Joy Kabiru3, Alain M’bongo Zindamoyen3, Hillary Rono1,4,
Ernest Ollando5, Joseph Wachira6, Rhoda Munene6, Timothy Onyuma7, Walter G. Jaoko8,
Mandeep S. Sagoo9,10,11, Helen A. Weiss12 and Matthew J. Burton1,10
1 International Centre for Eye Health, London School of Hygiene and Tropical Medicine, London, UK
2 Department of Ophthalmology, University of Nairobi, Nairobi, Kenya
3 PCEA Kikuyu Eye Unit, Kikuyu, Kenya
4 Kitale District Hospital, Kitale, Kenya
5 Sabatia Eye Hospital, Wodanga, Kenya
6 Kenyatta National Hospital, Nairobi, Kenya
7 Department of Pathology, MP Shah Hospital, Nairobi, Kenya
8 KAVI Institute of Clinical Research, University of Nairobi, Nairobi, Kenya
9 UCL Institute of Ophthalmology, London, UK
10 Moorfields Eye Hospital, London, UK
11 St. Bartholomew’s Hospital, London, UK
12 MRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK
Abstract objective To determine modifiable risk factors of ocular surface squamous neoplasia (OSSN) in
Kenya using disease-free controls.
methods Adults with conjunctival lesions were recruited at four eye care centres in Kenya and
underwent excision biopsy. An equal number of controls having surgery for conditions not affecting
the conjunctiva and unrelated to ultraviolet light were group-matched to cases by age group, sex and
eye care centre. Associations of risk factors with OSSN were evaluated using multivariable logistic
regression to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs). Continuous
variables were compared using the t-test or the Wilcoxon–Mann–Whitney U-test depending on their
distribution.
results A total of 131 cases and 131 controls were recruited. About two-thirds of participants were
female, and the mean age of cases and controls was 42.1 years and 43.3 years, respectively. Risk
factors for OSSN were HIV infection without antiretroviral therapy (ART) use (OR = 48.42; 95%
CI: 7.73–303.31) and with ART use (OR = 19.16; 95% CI: 6.60–55.57), longer duration of exposure
to the sun in the main occupation (6.9 h/day vs. 4.6 h/day, OR = 1.24; 95% CI: 1.10–1.40) and a
history of allergic conjunctivitis (OR = 74.61; 95% CI: 8.08–688.91). Wearing hats was protective
(OR = 0.22; 95% CI: 0.07–0.63).
conclusion Measures to prevent and control HIV, reduce sun exposure such as wearing hats and
control allergic conjunctivitis are recommended.
keywords ocular surface squamous neoplasia, risk factors, ultraviolet radiation, HIV, antiretroviral
therapy, allergic conjunctivitis
Introduction
Ocular surface squamous neoplasia (OSSN) is a spectrum
of disease in the conjunctiva and cornea that ranges from
intra-epithelial neoplasia to invasive squamous cell carci-
noma. It usually presents as a unilateral tumour on the
eye, centred around the corneal limbus (the junction
between the cornea and conjunctiva) [1].
The epidemiology, aetiology and pathophysiology of
OSSN are not well understood. There appear to be two
disease patterns: a milder form in temperate climates and
a more aggressive one in sub-Saharan Africa (SSA). In
SSA, both males and females have equal incidence rates,
although in prevalence series females constitute 60–70%,
in contrast to other regions where males predominate [2,
3]. It is unclear why the prevalence is not 1:1 in African
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series. The presentation of OSSN in SSA also is relatively
more aggressive, with a short history of 3–8 months com-
pared to one year in temperate climates [4–7], and
younger age of onset (30–40 years in SSA vs. 60–70 years
in temperate climates) [2, 3, 8]. Current evidence suggests
that multiple factors may combine to drive the disease
process. Case–control studies and cancer registry data
implicate ambient solar ultraviolet radiation (UVR)
among other factors. The risk of OSSN is higher in those
who spend more time outdoors and the incidence world-
wide varies with latitude peaking at 16°S, particularly in
the sunny areas of Eastern and Southern Africa, and also
Australia [2, 9–11]. This may be related to the Earth’s
23° tilt and elliptical orbit which brings it closer to the
sun during the southern summers (perihelion) than during
the northern summer (aphelion) [12]. The TP-53 gene
mutation, which is associated with UV radiation, has
been found more frequently in OSSN tissue [11, 13].
There is a strong association between OSSN and HIV
in SSA, and incidence rose sharply with the onset of the
HIV pandemic [14]. However, about 30% of people with
OSSN in SSA are not infected with HIV, suggesting that
other factors also contribute [2]. The association between
human papilloma virus (HPV) and OSSN is inconclusive
[15–20]. This is probably because of variations in
methodology and the specific HPV types that have been
looked for [2].
The importance of vitamin A in maintaining the health
of the ocular surface is established, and its deficiency
leads to goblet cell loss, desquamation and keratinisation
of the ocular surface [21]. Vitamin A deficiency (serum
retinol <30 lg/dl or <1.05 lmol/l) is common in HIV
patients [22]. The potential role of vitamin A deficiency
in OSSN has not previously been investigated. Cigarette
smoking, although associated with many cancers, has not
been conclusively shown to be associated with OSSN [2].
To date, case–control studies investigating risk factors
for OSSN have enrolled individuals with conjunctival
lesions suspected to be OSSN, which were excised and
sent for histopathology. Individuals with OSSN were
classified as ‘cases’ and those with benign lesions as ‘con-
trols’ [6, 11, 13, 23]. However, these are probably not
appropriate controls, as benign conjunctival lesions may
have some risk factors in common with OSSN. For exam-
ple, pterygia, actinic keratosis and papillomas, the most
common benign lesions, may also be associated with
solar UV radiation, p53 gene mutation and human papil-
lomavirus infection [24–27].
The aim of this study was to investigate the role of
multiple risk factors (HIV infection, vitamin A, cigarette
smoking, ultraviolet light exposure and occupation),
which are preventable or modifiable, by comparing OSSN
cases to disease-free controls presenting at four eye care
centres in Kenya.
Methods
Ethical approval
This study was approved by the Kenyatta National
Hospital – University of Nairobi Ethics and Research
Committee and the London School of Hygiene & Tropi-
cal Medicine Ethics Committee. All participants gave
informed written consent to take part. It adhered to the
tenets of the Declaration of Helsinki.
Study design
A frequency-matched case–control study design was used,
with a 1:1 case-to-control ratio. Matching was by age
(10-year age groups) and sex, as both are strong constitu-
tional factors associated with OSSN. Cases of OSSN
(subsequently confirmed by histology to have OSSN)
were compared with controls who had no conjunctival
lesion, attending for routine ophthalmic surgery that
involved incision of the conjunctiva. Controls were
recruited at the same ophthalmic clinics after cases were
enrolled.
Study setting
Recruitment was between July 2012 and July 2014 in
four eye care centres in Kenya, namely Kenyatta National
Hospital (KNH) Eye Clinic, Nairobi; PCEA Kikuyu Eye
Unit (KEU), Kikuyu near Nairobi; Sabatia Eye Hospital
(SEH), Vihiga about 350 km north-west of Nairobi near
Lake Victoria; and Kitale District Hospital (KDH) in the
North Rift Valley. These are busy eye units that receive
referrals from surrounding areas (Table 1).
Study population, inclusion and exclusion criteria
Both cases and controls were recruited from people
attending the eye clinic. Adult patients (aged >18 years)
with any histologically confirmed OSSN tumour (first
presentation or recurrence) were included as cases.
Controls were adult patients scheduled for ocular sur-
gery that involved a conjunctival incision for a disease
not involving the conjunctiva and unrelated to ultravio-
let light (such as trauma, squint or retinal surgery).
History of prior surgery in the index eye was an exclu-
sion criterion for controls. Eligible participants who
gave written informed consent to participate were
enrolled.
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Demographic and occupational data
Data on age, sex, marital status and educational history
were collected. Questions included the following: residen-
tial history (regions lived in for >1 year), lifetime occupa-
tional history (including whether based mainly indoors or
outdoors), hours of sun exposure on an average day, pat-
terns of wearing hats, caps or sunglasses, and cigarette
smoking history. Participants with regular partners who
smoked cigarettes were classified as passive smokers.
Clinical examination
For potential cases (participants with conjunctival
lesions), a detailed clinical and slit lamp examination was
performed, to document clinical features of the tumours.
High-resolution digital photographs were taken. For
potential controls, the ocular surface was examined at
the slit lamp before surgery to exclude any conjunctival
lesions.
Surgical excision and histopathology
All lesions were excised under local infiltration anaes-
thetic using an operating microscope with a 4-mm clear
margin, using the ‘no touch technique’ to minimise
tumour handling. Specimens were placed directly into
buffered formalin and subsequently examined at the
histopathology laboratory at the MP Shah Hospital,
Nairobi. All the histology slides were stained with
haematoxylin and eosin and examined by one pathologist
(TO). For controls, a 2-mm-by-2-mm piece of conjunc-
tiva was excised and immediately placed in RNAlater tis-
sue collection RNA stabilisation solution (Ambion Inc.,
Austin, Texas, USA) for further molecular studies, which
will be reported separately.
HIV/CD4 count assays
Individuals with a confirmed diagnosis of OSSN were
tested for HIV and CD4 cell count 4 weeks after the sur-
gery when they returned for results. Controls were tested
for HIV and CD4 at the time of surgery. Pre-test coun-
selling was provided individually to all participants by a
counsellor. Venous whole blood was tested at the Kenya
Aids Vaccine Institute (KAVI) for Clinical Research Lab-
oratory at the University of Nairobi for HIV initially
using Vironostika antigen/antibody kit (Biomerieux,
Marcy l’Etoile, France) then later the Alere Determine
HIV-1/2 Ag/Ab (Alere, CITY, USA) and Trinity Unigold
(Trinity Biotech, Jamestown, USA) when Vironostika
became unavailable. CD4 count was measured using
FacsCount (Becton Dickinson, Franklin Lakes, USA).
Samples from Sabatia Eye Hospital and Kitale District
Hospital were tested for HIV using Alere Determine
HIV-1/2 Ag/Ab (Alere, CITY, USA) and for CD4 count
using FacsCount (Becton Dickinson, Franklin Lakes,
USA). We also asked about antiretroviral (ART) use.
Serum vitamin A assays
Blood samples collected without EDTA were immediately
wrapped in aluminium foil to prevent degradation from
light. They were transported to the KAVI laboratory in a
cool box within an hour from nearby centres (KNH and
KEU) or couriered on ice packs from more distant centres
(SEH and KDH). On arrival, samples were immediately
centrifuged at 2500 revolutions per minute for 10 min in
a dimly lit room, aliquoted into cryovials, labelled,
rewrapped in aluminium foil and stored in a freezer at
80 °C. Samples were batched and shipped on dry ice to
the Tropical Diseases Research Centre’s Nutrition Unit in
Ndola, Zambia. Retinol was quantified using high-perfor-
mance liquid chromatography [28]. The quantitation of
retinol was performed using the SHIMADZU Prominence
HCT2010 HPLC (Kyoto, Japan). Individuals with serum
retinol <30 lg/dl were considered vitamin A deficient.
Table 1 Study Centres and the 2013 HIV prevalence in their
catchment areas [46]
Study centre County†
HIV
prevalence (%)
Kenyatta National
Referral Hospital*
Nairobi 8.0
Machakos 5.0
Kajiado 4.4
PCEA Kikuyu Hospital Kiambu 3.8
Muranga 5.2
Nyeri 4.3
Embu 3.7
Kirinyaga 3.3
Sabatia Eye Hospital Vihiga 3.8
Kakamega 5.9
Bungoma 3.2
Kisumu 19.3
Homa Bay 25.7
Siaya 23.7
Migori 14.7
Kitale District Hospital Trans Nzoia 5.1
Turkana 7.6
West Pokot 2.8
The prevalence data refer to adults of age 15–49 years. The
national prevalence was 6.0%.
*The national referral hospital receives patients from further
afield including counties that may be listed under other study
centres.
†The first county listed is where the study centre is located.
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Sample size determination
This case–control study was nested within a randomised
controlled trial of post-operative 5-fluorouracil eyedrops
to reduce recurrent OSSN. The sample size of 131 cases
and 131 controls provides 90% power to detect a differ-
ence in prevalence of a given exposure of 40% in con-
trols and 60% in cases.
Statistical analysis
Data were managed in an Access database (Microsoft),
cleaned and transferred into STATA version 12.1 (Stata-
Corp, College Station, Texas, USA) for analysis. In this
analysis, we compared the cases and controls for the pro-
portions with HIV/ART status, vitamin A deficiency,
cigarette smoking and for levels of UV radiation expo-
sure. We also compared cases and controls for the mean
or median for CD4 count, number of cigarettes smoked
daily and serum retinol levels. CD4 counts were graded
by the WHO criteria [29]. All analyses were adjusted for
age, sex and study centre. Multivariable logistic regres-
sion analysis was used to estimate odds ratios (ORs) and
95% confidence intervals (CIs). The likelihood ratio test
was used to assess statistical significance of associations.
Variables that were associated with the outcome on the
initial adjusted analyses at a level of P < 0.05 were
included in the multivariable analysis, and then those
with P < 0.2 were retained in the model.
Results
Five potential cases and six potential controls declined to
participate. 262 participants were recruited: 131 cases
and 131 controls were frequency-matched by age group
and sex. About two-thirds were females (72% of cases
and 65% of controls, P = 0.23). The mean age and stan-
dard deviation (SD) of cases and controls were 42.1 years
(SD = 13.1) and 43.3 years (SD = 13.2), respectively
(P = 0.43). The controls all had surgery for conditions
without primary conjunctival pathology: lacerations
(n = 41), traumatic cataract (n = 39), vitreous haemor-
rhage (n = 29), retinal detachment (n = 18) and squint
surgery (n = 4).
After adjusting for the matching variables, OSSN was
strongly associated with HIV infection (OR = 18.96,
95% CI: 8.87–40.5), lower CD4 count (OR = 37.33,
95% CI: 7.98–174.5 for CD4 < 200 cells/mm3 compared
with CD4 > 500 cells/mm3) and history of allergic con-
junctivitis (OR = 30.78, 95% CI: 4.05–234). There were
weaker associations with lower education level
(OR = 1.82, 95% CI: 1.03–3.21 for no education or
primary vs. completed secondary or more) and outdoor
occupations (OR = 1.73, 95% CI: 1.03–2.91; Table 2).
Residential area was not associated with OSSN status,
but there was some evidence of a higher odds of OSSN
among those who resided in Nyanza Province
(OR = 3.00, 95% CI: 1.04–8.65 compared with Nair-
obi). There was no evidence that current active smokers
were at higher risk than non-smokers (OR = 1.62, 95%
CI: 0.56–4.75) – the P value (0.03) was influenced by a
lower risk in passive smokers (OR = 0.54, 95% CI:
0.15–1.94). OSSN was also not associated with the dura-
tion of smoking (P = 0.79) or the number of cigarettes
smoked daily (P = 0.60). Cases had lower median levels
of serum retinol than controls (44.9 lg/dl vs. 51.0 lg/dl,
P = 0.03).
Independent risk factors for OSSN are shown in
Table 3. Participants who were HIV positive and not on
ART were at the greatest risk (adjusted OR = 48.42,
95% CI: 7.73–303.3 compared with HIV-negative partic-
ipants), and there was also a very strong association with
history of allergic conjunctivitis (adjusted OR = 74.61,
95% CI: 8.08–688.9). The duration of exposure to the
sun per day in their occupations was higher among cases
than controls (6.9 h/day vs. 4.6 h/day, P < 0.001). There
was also a strong independent protective effect of wear-
ing a hat or cap outdoors (OR = 0.22, 95% CI: 0.07–
0.63).
Discussion
OSSN appears to be a disease driven by multiple risk fac-
tors. In this study, we set out to examine several of these
in a large case–control study in Kenya nested within a
randomised controlled trial, and confirmed established
risk factors such as exposure to ultraviolet radiation and
HIV infection and some potential new ones such as aller-
gic conjunctivitis.
This study design has several strengths compared with
previous case–control studies. Most notably, previous
studies have used controls with benign lesions which
could be on the causal pathway for OSSN or could share
similar risk factors, and this is likely to underestimate the
magnitude of their effects. For example, HIV is an estab-
lished risk factor for OSSN, but we found a much stron-
ger association of HIV and OSSN than previously
reported in a meta-analysis of six case–control studies in
East and Southern Africa (summary OR = 6.17; 95% CI:
4.83–7.89) [2]. Five of those studies were conducted in
the era before ART programmes were available or scaled
up in the region while one was conducted in 2010 when
ART was available in Ugandan public hospitals and did
not report on ART use [30]. HIV is also associated with
4 © 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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more severe OSSN disease. A study in India that com-
pared HIV-infected OSSN patients with HIV-negative
OSSN patients found that HIV infection was associated
with larger tumours and a higher incidence of extension
to the cornea, sclera and orbit, but there were no data
reporting ART use [31]. Although we had CD4 data on
only 59 cases and 76 controls, it was intriguing that CD4
count was not a significant risk factor after multivariable
Table 2 Analysis of potential risk factors for ocular surface squamous neoplasia adjusted for age group, sex and study centre
Exposure Cases (N = 131)
Controls
(N = 131) OR (95% CI) P value
Marital status, No. (%) 0.37
Married 83 (63.4) 89 (67.9) 1 [Reference]
Single 22 (16.8) 26 (19.9) 0.91 (0.48–1.73)
Widowed 18 (13.7) 10 (7.6) 1.93 (0.84–4.45)
Divorced or separated 8 (6.1) 6 (4.6) 1.43 (0.47–4.31)
Highest education level, no. (%) 0.04
Completed secondary or more 46 (35.1) 68 (51.9) 1 [Reference]
Completed primary or some secondary 53 (40.5) 39 (29.8) 1.82 (1.03–3.21)
None or some primary 32 (24.4) 24 (18.3) 1.78 (0.90–3.52)
Residential area (province) 0.21
Nairobi 28 (21.4) 42 (32.1) 1 [Reference]
Rift Valley 36 (27.5) 28 (21.4) 1.93 (0.96–3.88)
Central 27 (20.6) 34 (26.0) 1.19 (0.59–2.40)
Eastern 13 (9.9) 9 (6.9) 2.17 (0.81–5.85)
Nyanza 14 (10.7) 7 (5.3) 3.00 (1.04–8.65)
Western 10 (7.6) 10 (7.6) 1.50 (0.55–4.11)
Coast 1 (0.8) 1 (0.8) 1.50 (0.09–25.52)
North-eastern 2 (1.5) 0 –
Duration of residence in home province, median (IQR), y 24 (10–39) 28 (14–40) – 0.10*
History of allergic conjunctivitis† 28 (21.5) 1 (0.9) 30.78 (4.05–233.75) <0.001
Location of current occupation, no. (%)† 0.02
Indoor 45 (34.9) 62 (48.1) 1 [Reference]
Outdoor 84 (65.1) 67 (51.9) 1.73 (1.03–2.91)
Duration in current occupation, median (IQR), y 10 (5–20) 15 (7–23) – 0.04*
Sun exposure per day in current occupation, mean (SD), h 6.9 (3.8) 4.6 (3.2) 1.22 (1.12–1.32) <0.001‡
Hat or cap worn outdoors, no. (%)† 19 (15.0) 32 (24.8) 0.60 (0.30–1.20) 0.07
Sunglasses worn outdoors, no. (%)† 10 (7.9) 16 (12.4) 0.66 (0.28–1.55) 0.11
Cigarette smoking (past), no. (%)† 0.10
No 93 (71.5) 90 (70.3) 1 [Reference]
Passive (spouse/partner smokes) 17 (13.1) 21 (16.4) 1.09 (0.47–2.53)
Yes 20 (15.4) 17 (13.3) 1.11 (0.54–2.31)
Cigarette smoking (current), no. (%)† 0.03
No 115 (89.2) 111 (88.1) 1 [Reference]
Passive (spouse/partner smokes) 4 (3.1) 9 (7.1) 0.54 (0.15–1.94)
Yes 10 (7.8) 6 (4.8) 1.62 (0.56–4.75)
Duration of cigarette smoking, mean (SD), y 13.5 (8.6) 12.7 (10.0) – 0.79‡
No. of cigarettes smoked daily, median (IQR), y 9 (5–20) 7 (5–10) – 0.60*
HIV infection§, no. (%) 62 (74.7) 14 (13.6) 18.96 (8.87–40.51) <0.001
HIV infection and ART use¶, no. (%) <0.001
HIV 21 (16.0) 89 (67.9) 1 [Reference]
HIV+/ART 17 (13.0) 2 (1.5) 38.54 (8.19–181.39)
HIV+/ART+ 40 (30.5) 12 (9.2) 14.30 (6.35–32.20)
No HIV or ART data 53 (40.5) 28 (21.4) 7.18 (3.67–14.05)
CD4 count**, median (IQR), cells/mm3 251 (118–670) 796 (619–1063) – <0.001*
CD4 WHO category, no.(%), cells/mm3 <0.001
≥500 20 (15.3) 64 (48.9) 1 [Reference]
350–499 6 (4.6) 9 (6.9) 2.39 (0.74–7.68)
© 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 5
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adjustment. There may have been confounding with ART
as those with low CD4 counts would be started on treat-
ment and their CD4 count would subsequently rise. We
observed that those on ART had higher mean CD4
counts than those who were not (see footnote Table 3).
There was also an overlap in the confidence intervals
between HIV-infected people on ART and not on ART
suggesting that ART did not seem to significantly change
the effect of HIV infection on OSSN. This is further sup-
ported by the observation that OSSN is still common in
Africa despite availability of ART programmes for over a
decade. Perhaps, the effect of HIV on OSSN may not be
through CD4 counts but rather a yet-to-be-understood
pathway. HIV-associated premature ageing could also
play a role in the aetiology as advancing age increases
cancer risk [32].
Another aspect of our study design is that we enrolled
controls after cases had been recruited. There may be sys-
tematic differences between incident and prevalent OSSN
cases which are difficult to identify in previous case–con-
trol studies that enrolled cases and controls concurrently.
Our study focused on modifiable risk factors to identify
strategies for prevention. We found a similar effect for
duration of solar ultraviolet exposure outdoors to a study
in Uganda (adjusted OR = 1.7; 95% CI: 1.2–2.4 for
cases exposed to 2–4 h and OR = 1.8; 95% CI: 1.1–3.1
for those exposed to ≥5 h daily) [11]. The association
between OSSN and UV radiation has been shown by
results from cancer registries and the previously men-
tioned case–control study in Uganda [2, 11, 33]. The lat-
ter had two types of controls per case: patients attending
the eye clinic for reasons other than OSSN, and patients
originally recruited as cases but whose histology was
non-OSSN [11]. UV radiation affects the nasal limbus
more than other parts of the eye which explains why
there is a higher proportion of both benign and malig-
nant conjunctival lesions nasally than temporally [4, 34,
35]. Although cases had worked for a shorter period at
their current occupations (10 years vs. 15 years,
P = 0.04), they were more likely to have outdoor occupa-
tions than controls (65% vs. 52%) and had longer daily
exposure to the sun at work (P < 0.001). The association
we observed between less education and OSSN could
have been due to those less educated people (particularly
incomplete secondary school level) having jobs with
Table 2 (Continued)
Exposure Cases (N = 131)
Controls
(N = 131) OR (95% CI) P value
200–349 11 (8.4) 1 (0.8) 39.24 (4.68–328.33)
<200 22 (16.8) 2 (1.5) 37.33 (7.98–174.50)
No CD4 data 72 (55.0) 55 (42.0) 3.84 (2.06–7.17)
Vitamin A deficiency (<30 lg/dl)††, no. (%) 5 (8.8) 5 (5.8) 1.30 (0.32–5.32) 0.50
Serum retinol, median (IQR), lg/dl 44.9 (37.6–56.2) 51.0 (39.7–64.7) – 0.03*
SD, standard deviation; IQR, interquartile range.
*Wilcoxon–Mann–Whitney U-test.
†There were missing data on allergic conjunctivitis (24 participants), occupational location [4], hat or sunglasses use [6] and cigarette
smoking [7].
‡t-test.
§The denominator here is 83 cases and 103 controls who were tested for HIV.
¶We used the combined HIV/ART variable because the effect of HIV would be related to ART use.
**There were 59 cases and 76 controls who had a CD4 test.
††The denominator here is 57 cases and 86 controls who had a vitamin A test.
Table 3 Multivariable logistic regression analysis of factors
associated with OSSN
Exposure Adj OR* (95% CI) P value
HIV infection and ART use* <0.001
HIV 1 [Reference]
HIV+/ART 48.42 (7.73–303.31)
HIV+/ART+ 19.16 (6.60–55.57)
No HIV or ART data 9.38 (3.78–23.29)
History of allergic conjunctivitis 74.61 (8.08–688.91) <0.001
Sun exposure in current
occupation
1.24 (1.10–1.40) 0.001
Hat or cap worn outdoors 0.22 (0.07–0.63) 0.01
Highest education level 1.55 (0.91–2.65) 0.11
The mean (SD) CD4 count with respect to HIV and ART was;
HIV- was 926(298) cells/mm3; HIV+/ART- was 258(196) cells/
mm3; HIV+/ART+ was 314(225) cells/mm3; and missing HIV/
ART data was 136 (101) cells/mm3.
*We used the combined HIV/ART variable because the effect of
HIV would be related to ART use.
6 © 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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greater sun exposure (means range from 6.5 to 8.4 h/day)
than controls (4.6 h/day), but it persisted on adjustment
suggesting residual confounding or an independent effect.
The observed protective effect of wearing hats while out-
doors is consistent with UV radiation being a risk factor
of OSSN. The earlier Uganda study did not find hats pro-
tective (OR = 1.3; 95% CI: 0.8–2.2) [11]. We did not
find sunglasses protective similar to the same Uganda
study.
We found a relatively high prevalence of history of
allergic conjunctivitis among cases (21.5%) which con-
trasts with previous studies. The aforementioned case–
control study in Uganda reported no OSSN cases with
allergic conjunctivitis, and a descriptive study in Tanzania
found a prevalence of 1.9% [11, 36]. The Uganda study
examined for allergy in the nasal quadrant of the con-
junctiva, but they were unlikely to find allergy in adults
in their 30s and 40s as typically the onset is in childhood
and is rare after the age of 30 years. Allergic conjunctivi-
tis is common in Africa. Studies in Ghana and Nigeria
found allergic conjunctivitis in up to 40% of school chil-
dren and 33% of university students, respectively [37,
38]. The disease also tends to be quite severe with limbal
hypertrophy as shown in a Rwandan study where 98%
of school children with vernal keratoconjunctivitis (VKC)
had limbal disease [39]. Although not fully understood,
limbal stem cells may be the progenitors in the patho-
physiology of OSSN [40]. It is unclear whether allergic
conjunctivitis or its treatment with steroids is the cause
per se. One hypothesis may be that chronic allergic con-
junctivitis is associated with a milieu of inflammation
mediators which increases the probability of DNA errors
during mitosis of stem cells at the limbus. Using corneal
confocal microscopy, a study found that patients with
VKC had more cells with a high nuclear-to-cytoplasm
ratio (26.4% vs. 7.5%), more activated cells (59% vs.
10%) and inflammatory cells (75.4% vs. 0) than controls
[41]. Another possible explanation is that prolonged ster-
oid use causes immunosuppression (like HIV might)
which predisposes to OSSN.
There was little evidence of an association with smok-
ing in this study, and prevalence of smoking was low.
Two studies in Uganda showed evidence of no effect of
current smoking compared to non-smokers [11, 42]. The
levels of serum retinol were lower in cases suggesting
that vitamin A may play a role. This is biologically plau-
sible as previous studies have demonstrated ocular sur-
face changes related to vitamin A deficiency such as
keratinisation which presents as leukoplakia, a frequent
feature of OSSN lesions [21]. Squamous metaplasia of
the ocular surface epithelium is also seen in retinol defi-
ciency and reversed by topical retinoid therapy [43].
Retinoic acid, a metabolite of retinol, has antitumour
effects and helps to maintain the pluripotency of limbal
stem cells through specific receptors in the cell nucleus
[44].
This study had several limitations. Selection bias may
be present if potential controls with a less serious disease
than OSSN were not inclined to participate. The refusal
rates were however not different for cases at 5 of 273
(1.8%) and 6 of 273 (2.2%) for controls. Recall bias
could not be ruled out as cases are more likely to
remember about exposures more than controls. We had
considerable missing data on HIV, CD4 count and vita-
min A as not all excised cases returned post-operatively
for testing. The classification of occupations is not ideal.
We would have preferred one that classifies occupations
by possible exposure to carcinogens. Existing systems
such as Kenya National Occupational Classification Sys-
tem (KNOCS) which is derived from the International
Standard Classification of Occupations (ISCO) are
designed for only economic purposes and not for epi-
demiological studies [45].
In conclusion, we identified modifiable risk factors for
OSSN. HIV control interventions are now available,
exposure to UV radiation can be reduced, and indeed we
found that wearing hats was protective, while allergic
conjunctivitis can be better managed in younger people.
The results of this study corroborate what is known
about the pathophysiology of OSSN where the limbus
stem cells appear to be the main focus of disease. How-
ever, the latency period between first exposure to these
risk factors and causation of OSSN is still not known.
The role of CD4 count in OSSN remains to be eluci-
dated, and why OSSN usually affects one eye is still an
enigma. Measures to control HIV, prevent sun exposure
such as wearing hats and control allergic conjunctivitis
are recommended.
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